Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of August 19, 2026, GILD trades at $144.00 with a market cap of $172.25B and a P/E ratio of -55.06. GILD moved +3.19% today. Year to date, GILD is +16.86%; over the trailing twelve months it is +21.57%. Its 52-week range spans $88.57 to $157.29. Analyst consensus is strong buy with an average price target of $158.71. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for GILD combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $144.00 |
| Market Cap | $172.25B |
| P/E Ratio | -55.06 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $88.57 |
| Volume | 4.36M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $158.71.